How CDMO Partnerships Can Accelerate Cell and Gene Therapy Commercialization

Moving a cell or gene therapy from clinical development toward commercial supply requires coordination across process development, manufacturing, analytical testing, quality, regulatory readiness, and supply chain planning. Managing these activities internally can create significant operational and technical demands for biotechnology and pharmaceutical companies.

Strategic end to end CDMO services can help developers bring these capabilities together under a coordinated manufacturing strategy. Instead of managing multiple specialized suppliers and internal functions independently, developers can work with a partner that supports several stages of the product lifecycle.

For cell and gene therapy programs, this integrated model can improve continuity, simplify technology transfer, and help development teams prepare earlier for commercial manufacturing requirements.

Why Commercialization Is Complex for Cell and Gene Therapies

Cell and gene therapies have manufacturing requirements that differ substantially from conventional pharmaceutical products.

The manufacturing process may involve complex biological starting materials, specialized culture or modification steps, sensitive handling conditions, and product-specific analytical methods.

As a therapy moves toward commercialization, developers must also demonstrate that manufacturing processes can consistently produce a product meeting predefined quality requirements.

This creates several interconnected challenges:

Process scalability, analytical method maturity, manufacturing capacity, GMP compliance, quality control, supply-chain reliability, technology transfer, and cost management.

A CDMO partnership can help address these requirements through coordinated technical and operational support.

What Are End to End CDMO Services?

End-to-end CDMO services encompass multiple stages of development and manufacturing rather than focusing on a single activity.

Depending on the provider and program, these services can include:

Process development, manufacturing, analytical testing, quality control, technology transfer, and support for clinical and commercial production.

The value of this model is coordination.

When process development, manufacturing, and analytical teams work within an integrated framework, decisions made during one stage can be considered in the context of downstream manufacturing and release requirements.

This can be particularly valuable for advanced therapies where late-stage process changes can create significant technical and regulatory consequences.

How CDMO Partnerships Can Accelerate Commercialization

1. Connecting Process Development With Manufacturing

A commercially viable process needs to be more than technically successful at laboratory scale.

Developers must consider whether it can be reproduced, controlled, transferred, and scaled.

A CDMO with process development and manufacturing capabilities can help evaluate these considerations earlier.

Process development activities can focus on identifying critical process parameters, optimizing manufacturing conditions, and improving process consistency.

This creates a stronger foundation for later GMP production.

2. Reducing Technology Transfer Complexity

Technology transfer can become challenging when process knowledge is divided between different organizations.

A developer may have one team responsible for process development, another organization performing analytical testing, and a separate manufacturer responsible for GMP production.

Each transition introduces opportunities for information gaps.

An integrated CDMO relationship can reduce some of these handoffs by maintaining greater continuity between development and manufacturing activities.

3. Supporting GMP Readiness

Commercialization requires manufacturing processes and quality systems capable of operating under appropriate GMP controls.

A CDMO can provide access to controlled manufacturing environments, established quality systems, trained personnel, and relevant operational infrastructure.

This can allow developers to focus internal resources on clinical development, regulatory strategy, and commercial planning while relying on an experienced manufacturing partner for defined operational activities.

The Importance of Analytical Testing

Manufacturing cannot be separated from analytical strategy.

Immunoassay testing services, for example, can provide targeted information about proteins, cytokines, biomarkers, or other biological components relevant to product characterization.

These methods can complement flow cytometry, molecular testing, microbiological testing, potency assays, and other analytical approaches.

An integrated analytical strategy helps developers understand whether manufacturing changes influence relevant product characteristics.

As programs progress toward commercialization, analytical methods may also need additional development, qualification, validation, or transfer depending on their intended use.

Analytical Testing and Commercial Release

Commercial manufacturing requires an analytical strategy that can support routine batch assessment.

Testing may address attributes such as identity, purity, viability, potency, microbiological safety, and other product-specific quality characteristics.

The exact testing package depends on the therapy and applicable requirements.

An experienced CDMO can help developers consider analytical requirements alongside manufacturing timelines.

This is important because laboratory capacity and test turnaround times can become bottlenecks as production volumes increase.

Improving Manufacturing Scalability

Commercialization often requires a transition from relatively limited clinical production to more predictable and recurring supply.

This does not always mean simply increasing batch size.

Developers may need to improve equipment utilization, manufacturing scheduling, process consistency, raw material supply, facility capacity, and QC throughput.

A cell therapy CDMO can support this transition by providing manufacturing infrastructure and technical expertise aligned with the program's anticipated requirements.

Capacity planning should consider expected demand, manufacturing cycle times, product characteristics, and future expansion requirements.

CDMO Partnerships and Supply Chain Planning

Cell and gene therapy manufacturing can depend on specialized raw materials, single-use components, reagents, cryogenic storage, and other critical supplies.

Supply interruptions can affect production schedules and clinical or commercial availability.

A CDMO partnership can provide an opportunity to evaluate supply-chain risks alongside manufacturing planning.

Developers should consider supplier qualification, material availability, lead times, alternative suppliers, storage requirements, and potential changes in material specifications.

These considerations should be addressed before commercial demand increases.

Regulatory and Quality Considerations

Commercialization requires evidence that the manufacturing process and quality system are appropriately controlled.

Important areas can include:

GMP compliance, documentation, deviation management, change control, environmental monitoring, analytical method control, equipment qualification, personnel training, and batch release processes.

The manufacturing partner should have quality systems appropriate to the intended manufacturing activities.

Developers should also establish clear responsibilities between their organization and the CDMO.

A well-defined quality agreement can clarify responsibilities for testing, deviations, change management, investigations, documentation, and batch disposition.

Choosing the Right CDMO Partner

Not every CDMO is suited to every cell and gene therapy program.

A partner evaluation should consider more than facility capacity.

Technical Expertise

Does the CDMO understand the specific therapy modality and manufacturing process?

Analytical Capabilities

Can the partner support the required characterization, bioanalytical, and release testing?

GMP Infrastructure

Are facilities, quality systems, and manufacturing controls appropriate for the intended stage?

Technology Transfer

Does the CDMO have experience transferring processes and analytical methods?

Commercial Scalability

Can the partner support increasing production requirements over time?

Communication

Are responsibilities, timelines, decision-making processes, and escalation pathways clearly defined?

The right partnership should align technical capability with the developer's long-term commercialization strategy.

When Should Developers Engage a CDMO?

Engaging a CDMO only when commercial manufacturing is approaching can create unnecessary pressure.

Early engagement can provide useful input into process design, analytical strategy, facility requirements, and technology transfer planning.

However, the appropriate timing depends on the development stage, internal capabilities, funding strategy, and manufacturing model.

For many programs, establishing a CDMO relationship during process development can help ensure that the manufacturing process is developed with eventual GMP production and commercialization in mind.

Common Mistakes to Avoid

Selecting a Partner Based Only on Price

Lower initial costs may not translate into lower total development or manufacturing costs.

Treating Manufacturing and Analytics Separately

Analytical requirements should be considered alongside manufacturing and release strategy.

Delaying Technology Transfer Planning

Late technology transfer can create schedule pressure and reveal process knowledge gaps.

Focusing Only on Clinical Supply

Commercial requirements can differ significantly from clinical production needs.

Failing to Define Responsibilities

Clear ownership of quality, testing, deviations, changes, documentation, and release decisions is essential.

A Practical CDMO Partnership Framework

Developers can evaluate potential partners using five core areas:

Technical fit: Can the CDMO support the therapy and process?

Quality fit: Are its quality systems appropriate for the program?

Analytical fit: Can it support characterization and release testing?

Capacity fit: Can it meet current and future manufacturing requirements?

Strategic fit: Can it support the program's long-term commercialization pathway?

This framework can help teams move beyond facility availability and evaluate the complete partnership.

Future Outlook

As cell and gene therapy programs progress toward commercialization, integrated manufacturing models are likely to become increasingly important.

Developers will need manufacturing partners capable of supporting increasingly mature processes, robust analytical strategies, scalable capacity, and strong quality systems.

At the same time, automation, closed processing, platform manufacturing, and advanced analytical technologies may improve manufacturing efficiency and consistency.

The strongest CDMO partnerships will likely be those that combine technical expertise with early strategic planning and transparent collaboration.

Conclusion

Commercializing a cell or gene therapy requires coordinated decisions across development, manufacturing, analytical testing, quality, technology transfer, and supply chain management.

End to end CDMO services can help simplify this complexity by connecting multiple activities under a coordinated manufacturing strategy.

For developers, the right partner should offer more than production capacity. Process development expertise, analytical capabilities, GMP infrastructure, technology transfer experience, quality systems, and commercial scalability all contribute to a successful partnership.

Xellera Therapeutics supports biotechnology and pharmaceutical companies with cell and gene therapy manufacturing, process development, bioanalytical testing, quality control and release testing, and technology transfer capabilities designed to support advanced therapy programs from development through clinical and commercial manufacturing.

FAQs

What are end to end CDMO services for cell and gene therapy?

End to end CDMO services can integrate multiple stages of a therapy program, including process development, GMP manufacturing, analytical testing, quality control, technology transfer, and support for clinical and commercial production.

How can a CDMO accelerate cell and gene therapy commercialization?

A CDMO can help by connecting process development with manufacturing, supporting GMP production, simplifying technology transfer, coordinating analytical testing, and providing scalable manufacturing infrastructure.

When should a cell therapy developer engage a CDMO?

Developers can engage a CDMO during process development or earlier to incorporate manufacturing, analytical, quality, and scalability considerations into the development strategy.

Why are analytical testing services important for commercialization?

Analytical testing provides evidence about product quality and biological characteristics. It also supports process development, comparability, quality control, and, where appropriate, product release.

What should developers consider when selecting a cell therapy CDMO?

Developers should evaluate technical expertise, GMP infrastructure, analytical capabilities, quality systems, technology transfer experience, manufacturing capacity, scalability, communication, and long-term strategic fit.